Form 6-K ROGERS COMMUNICATIONS For: Mar 31
Tweet
Share
E-mailUNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
________________________________________________
FORM 6-K
________________________________________________
Report of Foreign Private Issuer
Pursuant to Rule 13a-16 or 15d-16
under the Securities Exchange Act of 1934
________________________________________________
For the month of April, 2026
Commission File Number 001-10805
________________________________________________
ROGERS COMMUNICATIONS INC.
(Translation of registrant’s name into English)
________________________________________________
333 Bloor Street East
10th Floor
Toronto, Ontario M4W 1G9
Canada
(Address of principal executive offices)
________________________________________________
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:
Form 20-F o Form 40-F þ
Signatures
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| ROGERS COMMUNICATIONS INC. | |||||||||||
| By: | /s/ Glenn Brandt | ||||||||||
| Name: Glenn Brandt | |||||||||||
| Title: Chief Financial Officer | |||||||||||
Date: April 22, 2026
Exhibit Index
| Exhibit Number | Description of Document | |||||||
| 99.1 | Management's Discussion and Analysis of Rogers Communications Inc. for the first quarter ended March 31, 2026 | |||||||
| 99.2 | Interim Condensed Consolidated Financial Statements of Rogers Communications Inc. for the first quarter ended March 31, 2026 | |||||||
| 99.3 | Earnings Release of Rogers Communications Inc. for the first quarter ended March 31, 2026 | |||||||
ATTACHMENTS / EXHIBITS
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Rogers Donates $1 Million to 2026 Rogers Charity Classic
- Innovent Biologics Announces First Patient Dosed in a Phase 3 Clinical Trial of IBI3003(GPRC5D/BCMA/CD3 Tri-specific Antibody) for the Treatment of Multiple Myeloma
- Antengene Announces Exclusive License Agreement with MPM BioImpact-Established K2 Therapeutics for ATG-106 and Option for Undisclosed Bispecific TCE
Create E-mail Alert Related Categories
SEC FilingsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
